|
1
|
Rajkumar SV: Multiple myeloma: Every year
a new standard? Hematol Oncol. 37 (Suppl 1):S62–S65. 2019.
View Article : Google Scholar
|
|
2
|
Vozella F, Fazio F, Lapietra G, Petrucci
MT, Martinelli G and Cerchione C: Monoclonal antibodies in multiple
myeloma. Panminerva Med. 63:21–27. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Čolović M, Jurisic V, Bila J, Čolović N
and Palibrk V: FGF-R3 and OPG expression in patient with multiple
myeloma following systemic sclerosis: Case report and review of the
literature. Int J Hematol. 93:228–231. 2011. View Article : Google Scholar
|
|
4
|
St-Germain JR, Taylor P, Tong J, Jin LL,
Nikolic A, Stewart II, Ewing RM, Dharsee M, Li Z, Trudel S and
Moran MF: Multiple myeloma phosphotyrosine proteomic profile
associated with FGFR3 expression, ligand activation, and drug
inhibition. Proc Natl Acad Sci USA. 106:20127–20132. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Deligiorgi MV, Panayiotidis MI, Griniatsos
J and Trafalis DT: Harnessing the versatile role of OPG in bone
oncology: Counterbalancing RANKL and TRAIL signaling and beyond.
Clin Exp Metastasis. 37:13–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Siegel DS, Schiller GJ, Samaras C, Sebag
M, Berdeja J, Ganguly S, Matous J, Song K, Seet CS, Talamo G, et
al: Pomalidomide, dexamethasone, and daratumumab in relapsed
refractory multiple myeloma after lenalidomide treatment. Leukemia.
34:3286–3297. 2020. View Article : Google Scholar
|
|
7
|
Osmani L, Askin F, Gabrielson E and Li QK:
Current WHO guidelines and the critical role of immunohistochemical
markers in the subclassification of non-small cell lung carcinoma
(NSCLC): Moving from targeted therapy to immunotherapy. Semin
Cancer Biol. 52:103–109. 2018. View Article : Google Scholar
|
|
8
|
Jurišić V, Obradovic J, Pavlović S and
Djordjevic N: Epidermal growth factor receptor gene in
non-small-cell lung Cancer: The importance of promoter polymorphism
investigation. Anal Cell Pathol (Amst). 2018:61921872018.
|
|
9
|
Suda K, Onozato R, Yatabe Y and Mitsudomi
T: EGFR T790M mutation: A double role in lung cancer cell survival?
J Thorac Oncol. 4:1–4. 2009. View Article : Google Scholar
|
|
10
|
Montironi C, Muñoz-Pinedo C and Eldering
E: Hematopoietic versus Solid Cancers and T cell dysfunction:
Looking for similarities and distinctions. Cancers (Basel).
13:2842021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Agarwal R, Gupta R, Bhaskar A, Sharma A,
Thulkar S and Kumar L: Synchronous presentation of multiple myeloma
and lung cancer. J Clin Oncol. 26:5814–5816. 2008. View Article : Google Scholar
|
|
12
|
Castaneda O and Baz R: Multiple myeloma
genomics-A concise review. Acta Med Acad. 48:57–67. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ji SH, Park JO, Lee J, Oh MJ, Lim DH, Park
BB, Park KW, Lee SH, Kim K, Kim WS, et al: Three cases of
synchronous solid tumor and multiple myeloma. Cancer Res Treat.
36:338–340. 2004. View Article : Google Scholar
|
|
14
|
Osipova MV and Men'shakova SN: A case of a
combination of multiple myeloma and lung cancer. Ter Arkh.
69:64–65. 1997.(In Russian). PubMed/NCBI
|
|
15
|
Lin J, Zhu H, Lu X, Yang B, Han W, Dai H
and Wang Y: Autologous cytokine-induced killer cells in the
treatment of multiple myeloma concomitant with lung cancer and
paraneoplastic dermatoses. Intern Med. 49:2341–2346. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goto T, Maeshima A, Oyamada Y and Kato R:
Definitive diagnosis of multiple myeloma from rib specimens
resected at thoracotomy in a patient with lung cancer. Interact
Cardiovasc Thorac Surg. 10:1051–1053. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zuo W, Zhu X, Yang J, Mei Z, Deng M, Lin
Q, Song Y and Yin Q: Bortezomib combined with lenalidomide as the
first-line treatment for the rare synchronous occurrence of
multiple myeloma and pulmonary adenocarcinoma: A case report.
Medicine (Baltimore). 96:e57872017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kaiser MF, Croft J, Shah P, Yousaf N and
Popat S: Durable response of multiple myeloma and non-small cell
lung cancer with simultaneous, biologically targeted treatment. Br
J Haematol. 189:e1–e3. 2020. View Article : Google Scholar
|
|
19
|
Wang Z, Deng H, Zhang L, Dai Y, Li X, Lin
X, Wei J and Zou X: Daratumumab for Refractory IgD multiple myeloma
with lung cancer and persistent thrombocytopenia: A Case Report.
Clin Lab. Nov 1–2021.(Epub ahead of print). doi:
10.7754/Clin.Lab.2021.210405. View Article : Google Scholar
|
|
20
|
Marinopoulos S, Skorda L, Karatapanis S
and Rasidakis A: Multiple myeloma emerging after chemotherapy for
non-small-cell lung cancer. Med Oncol. 25:415–418. 2008. View Article : Google Scholar
|
|
21
|
Rao L, Giannico D, Leone P, Solimando AG,
Maiorano E, Caporusso C, Duda L, Tamma R, Mallamaci R, Susca N, et
al: HB-EGF-EGFR signaling in bone marrow endothelial cells mediates
angiogenesis associated with multiple myeloma. Cancers (Basel).
12:1732020. View Article : Google Scholar
|
|
22
|
Chen Y, Huang R, Ding J, Ji D, Song B,
Yuan L, Chang H and Chen G: Multiple myeloma acquires resistance to
EGFR inhibitor via induction of pentose phosphate pathway. Sci Rep.
5:99252015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang X, Ye H, He M, Zhou X, Sun N, Guo W,
Lin X, Huang H, Lin Y, Yao R and Wang H: lncRNA PDIA3P interacts
with c-Myc to regulate cell proliferation via induction of pentose
phosphate pathway in multiple myeloma. Biochem Biophys Res Commun.
498:207–213. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu R, Li W, Tao B, Wang X, Yang Z, Zhang
Y, Wang C, Liu R, Gao H, Liang J and Yang W: Tyrosine
phosphorylation activates 6-phosphogluconate dehydrogenase and
promotes tumor growth and radiation resistance. Nat Commun.
10:9912019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mashimo K, Tsubaki M, Takeda T, Asano R,
Jinushi M, Imano M, Satou T, Sakaguchi K and Nishida S:
RANKL-induced c-Src activation contributes to conventional
anti-cancer drug resistance and dasatinib overcomes this resistance
in RANK-expressing multiple myeloma cells. Clin Exp Med.
19:133–141. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jurisić V and Colović M: Correlation of
sera TNF-alpha with percentage of bone marrow plasma cells, LDH,
beta2-microglobulin, and clinical stage in multiple myeloma. Med
Oncol. 19:133–139. 2002. View Article : Google Scholar
|
|
27
|
Jurisic V, Colovic N, Konjevic G, Minic I
and Colovic M: An aggressive extramedullary cutaneous plasmacytoma
associated with extreme alterations in the innate immune system.
Onkologie. 33:113–115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iqbal J, Kumar K, Sun L and Zaidi M:
Selective upregulation of the ADP-ribosyl cyclases CD38 and CD157
by TNF but not by RANK-L reveals differences in downstream
signaling. Am J Physiol Renal Physiol. 291:F557–F566. 2006.
View Article : Google Scholar
|
|
29
|
Chen J, Fang M, Chen X, Yi C, Ji J, Cheng
C, Wang M, Gu X, Sun Q and Gao C: N-glycosylation of serum proteins
for the assessment of patients with IgD multiple myeloma. BMC
Cancer. 17:8812017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Van de Donk NWCJ, Richardson PG and
Malavasi F: CD38 antibodies in multiple myeloma: Back to the
future. Blood. 131:13–29. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ehlerding EB, England CG, Jiang D, Graves
SA, Kang L, Lacognata S, Barnhart TE and Cai W: CD38 as a PEt
imaging target in lung cancer. Mol Pharm. 14:2400–2406. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hogan KA, Chini CCS and Chini EN: The
Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer,
Aging, and Metabolic Diseases. Front Immunol. 10:11872019.
View Article : Google Scholar
|
|
33
|
Yang R, Elsaadi S, Misund K, Abdollahi P,
Vandsemb EN, Moen SH, Kusnierczyk A, Slupphaug G, Standal T, Waage
A, et al: Conversion of ATP to adenosine by CD39 and CD73 in
multiple myeloma can be successfully targeted together with
adenosine receptor A2A blockade. J Immunother Cancer.
8:e0006102020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Giatromanolaki A, Kouroupi M, Pouliliou S,
Mitrakas A, Hasan F, Pappa A and Koukourakis MI: Ectonucleotidase
CD73 and CD39 expression in non-small cell lung cancer relates to
hypoxia and immunosuppressive pathways. Life Sci. 259:1183892020.
View Article : Google Scholar
|
|
35
|
Horenstein AL, Bracci C, Morandi F and
Malavasi F: CD38 in adenosinergic pathways and metabolic
Re-programming in human multiple myeloma cells: In-tandem insights
from basic science to therapy. Front Immunol. 10:7602019.
View Article : Google Scholar
|
|
36
|
Fortunato O, Belisario DC, Compagno M,
Giovinazzo F, Bracci C, Pastorino U, Horenstein A, Malavasi F,
Ferracini R, Scala S, et al: CXCR4 inhibition counteracts
immunosuppressive properties of metastatic NSCLC stem cells. Front
Immunol. 11:021682020. View Article : Google Scholar
|
|
37
|
Vaisitti T, Aydin S, Rossi D, Cottino F,
Bergui L, D'Arena G, Bonello L, Horenstein AL, Brennan P, Pepper C,
et al: CD38 increases CXCL12-mediated signals and homing of chronic
lymphocytic leukemia cells. Leukemia. 24:958–969. 2010. View Article : Google Scholar
|
|
38
|
Gao L, Liu Y, Du X, Ma S, Ge M, Tang H,
Han C, Zhao X, Liu Y, Shao Y, et al: The intrinsic role and
mechanism of tumor expressed-CD38 on lung adenocarcinoma
progression. Cell Death Dis. 12:6802021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bu X, Kato J, Hong JA, Merino MJ, Schrump
DS, Lund FE and Moss J: CD38 knockout suppresses tumorigenesis in
mice and clonogenic growth of human lung cancer cells.
Carcinogenesis. 39:242–251. 2018. View Article : Google Scholar : PubMed/NCBI
|
